RMDM have helped to develop new technology which can detect all cancers at every stage with extremely high accuracy.
Non-invasive blood test set to revolutionise cancer diagnostics, alleviating financial pressure on NHS.
Ground-breaking technology that can detect all cancers at every stage with extremely high accuracy is ready to launch in the UK.
The start of the art PanTum Detect screening test is a non-invasive and low-cost blood test. It can detect any cancer at any stage of its growth with a 99.05% specificity and 97.5% sensitivity. This transformative technology is already on the market across the world, including in Holland and Germany. Building on this, RMDM is delighted to have been rigorously tested and validated in the UK at the Centre for Health and Human Performance (CHHP) at 76 Harley Street in London.
As one in two of us in the UK will develop cancer in our lifetime, there is an urgent need for better diagnosis. Screening programmes in the UK remain chronically limited and out of 200 types of cancers, the UK currently provides screening services for just three. Providing accurate and inexpensive screening is vital in order to increase cancer survival rates.
RMDM is determined to extend its reach as wide as possible in the UK to ensure millions of people have access to its life saving diagnostic technology, ensuring the UK now has the opportunity to revolutionise cancer diagnostics and alleviate the financial burden on the NHS.
Ali Ghaidan, Chief Executive Officer at RMDM, said:
“We are very excited to expand our German technology into the UK market. At RMDM, we can detect cancer quickly, accurately and inexpensively and embracing this technology will be essential for the government to fulfil its early intervention promise.
“Working in collaboration with the Centre for Health and Human Performance is an excellent first step into ensuring our technology is available across the UK.”
Elizabeth Moore, Managing Director at the Centre for Health and Human Performance, said:
“Myself and the team at CHHP are absolutely thrilled to be involved in the revolutionary launch of the PanTum blood test, an innovation in cancer blood testing. CHHP has been involved in the long process of trialling and testing for many months in order to validate the test, which is now ready for the UK market.
“The PanTum test has emerged as a unique test to the UK market, with minimal invasion and can screen for cancer before it is too late. The blood test is a significant breakthrough in proactive medical management that will enable patients and Doctors alike to detect much earlier change in metabolism that differentiate cancer cells from normal cells at such an early stage. We look forward to seeing how the development of this test within the UK can grow to a nationwide service.”
Dr Nyjon Eccles BSc MBBS MRCP PhD, the Natural Doctor Clinic, said:
“Current cancer screening generally detects cancer too late, i.e. when it is firmly established. Detecting the earliest signs of cancer presence has been a major challenge to doctors and scientists over the years; and is still the case.
“I believe that the PanTum blood test represents a significant potential breakthrough in that it is based on detection of the much earlier changes in metabolism that differentiate cancer cells from normal cells and that occur when a cancer is more juvenile. Results thus far suggest that the Pantum test has a high degree of accuracy. The test measures two critical cell markers APO10 and TKTL1”.
Dr Ahmed Bourghida, Chief Scientific Officer at RMDM, said:
“Following extensive research, investment and development, we are now in a position to revolutionise cancer care in the UK. Early detection of cancer is absolutely vital when it comes to improving cancer outcomes and saving lives, and our unique, non-invasive blood test will take away the fear factor that many people feel around biopsies, giving the NHS the confidence to run more universal screening campaigns.”
